Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
An announcement from Ascendis Pharma ( (ASND) ) is now available.
On February 12, 2025, Ascendis Pharma announced a new initiative where its Board of Directors authorized a share repurchase program and a net settlement of Restricted Stock Units (RSUs) totaling approximately $25 million. The share repurchase program, specifically, will allow the company to buy back up to $18.25 million in American Depositary Shares (ADSs), aligning with U.S. securities regulations. This strategic move aims to preserve about 200,000 ADSs as treasury shares, potentially enhancing shareholder value and signaling confidence in the company’s financial health.
More about Ascendis Pharma
Ascendis Pharma is a Denmark-based company engaged in the pharmaceutical industry. The company focuses on developing new therapies to address unmet medical needs by utilizing its unique TransCon technology platform.
YTD Price Performance: -13.40%
Average Trading Volume: 450,810
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $7.14B
For detailed information about ASND stock, go to TipRanks’ Stock Analysis page.
